Pulmonary TNFα is a critical mediator in Adult Respiratory Distress Syndrome

Abstract

The development of effective pharmacotherapies to combat the Adult Respiratory Distress Syndrome (ARDS) is critically dependent upon: (1) the development of clinically-relevant animal models; (2) identification of inflammatory mediators centrally involved in eliciting lung injury; (3) understanding the inter-relationships or 'cross-talk' between pro and anti-inflammatory mediators which modulate the lung inflammation; and (4) the application of molecular techniques to isolate potentially novel genes involved in the development of ARDS. In this paper, we will present evidence from a rat model of microvascular lung injury produced by interleukin-2 (IL-2), that pulmonary TNFα is a primary and pivotal mediator of lung injury and that different modes of TNFα inhibition may represent feasible strategies to prevent ARDS. Furthermore, we will describe how the application of Differential Display Reverse Transcriptase Polymerase Chain Reaction (DDRT-PCR) can allow the rapid isolation of partial fragments of potentially new genes involved in ARDS. The products of such genes could represent future target sites for pharmacotherapeutic intervention.

Get full access to this article

View all access options for this article.

References

Demling RH Current concepts on the Adult Respiratory Distress Syndrome. Circ Shock 1990; 30: 297-310.

Swank DS , Moore SB Roles of the neutrophil and other mediators in adult respiratory distress syndrome. Mayo Clin Proc 1989; 64: 1118-1132.

Sibille Y. , Reynolds HY Macrophages and polymorphonuclear neutrophils in lung defense and injury. Am Rev Respir Dis 1990; 141: 471-501.

Roberts DJ , Davies JM , Evans CC , Bell M. , Mostafa LM Tumor necrosis factor and adult respiratory distress syndrome. Lancet 1989; ii: 1043-1044.

Jorens PG , Van Damme J. , De Backer W. et al. Interleukin 8 (IL-8) in the bronchoalveolar lavage fluid from patients with the adult respiratory distress syndrome (ARDS) and patients at risk for ARDS. Cytokine 1992; 4: 592-597.

Kubes P. Polymorphonuclear leukocyte - endothelium interactions: a role for pro-inflammatory and anti-inflammatory molecules. Can J Physiol Pharmacol 1993; 71: 88-97.

Wayne-Smith C. Endothelial adhesion molecules and their role in inflammation. Can J Physiol Pharmacol 1993 , 71: 76-87.

Pober JS , Cotran RS Cytokines and endothelial cell biology. Physiol Rev 1990; 70: 427-451.

Rosenstein M. , Ettinghausen SE , Rosenberg SA Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. J Immunol 1986; 137: 1735-1742.

10.

Baumgartner JD Anti-endotoxin antibodies: a critical appraisal . In: Lamy M , Thijs LG eds. Mediators of Sepsis. New York: Springer-Verlag, 1992: 315-328.

11.

Welbourne R. , Goldman G. , Kobitz L. et al. Involvement of thromboxane and neutrophils in multiple-system organ edema with interleukin-2. Ann Surg 1990; 212: 728-733.

12.

Welbourne R. , Goldman G. , Kobzik L. et al. Interleukin-2 induces early multisystem organ edema mediated by neutrophils. Arch Surg 1991; 214: 181-186.

13.

Rabinovici R. , Sofronski MD , Renz JF et al. Platelet activating factor mediates interleukin-2 induced lung injury in the rat. J Clin Invest 1992; 89: 1669-1673.

14.

Chang SW , Feddersen CO , Hensen PM et al. Platelet-activating factor mediates hemodynamic changes and lung injury in endotoxin-treated rats. J Clin Invest 1987; 79: 1498-1509.

15.

Rabinovici R. , Sofronski MD , Borboroglu P. et al. Interleukin-2-induced lung injury: the role of complement. Circ Res 1994; 74: 329-335.

16.

Semmler J. , Wachtel H. , Endres S. The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor-α production by human mononuclear cells. Int J Immunopharmacol 1993; 115: 409-413.

17.

Han J. , Huez G. , Beutler B. Interactive effects of the tumor necrosis factor promoter and 3'-untranslated regions. J Immunol 1991; 146: 1843-1848.

18.

Han J. , Brown T. , Beutler B. Endotoxin-responsive sequences control cachectin/tumor necrosis factor biosynthesis at the translational level. J Exp Med 1990 ; 171: 465-475.

19.

Rabinovici R. , Neville LF , Borboroglu P. et al. Locally-produced TNFα mediates interleukin-2-induced lung injury. Submitted.

20.

Fong Y. , Tracey KJ , Moldawer LL et al. Antibodies to cachectin/TNF reduce interleukin-1β and interleukin-6 appearance during lethal bacteremia. J Exp Med 1989; 170: 1627-1633.

21.

Butler LD , Mohler KM , Layman NK et al. IL-2-induced systemic toxicity: induction of mediators and immunopharmacologic intervention. Immunopharmacol Immunotoxicol 1989; 11: 445-487.

22.

Waage A. , Halstensen A. , Shalaby R. et al. Local production of tumor necrosis factor α, interleukin 1 and interleukin 6 in meningococcal meningitis: relation to the inflammatory response. J Exp Med 1989; 170: 1859-1867.

23.

Coletti LM , Kunkel SL , Walz A. et al. Chemokine expression during hepatic ischemia/reperfusion-induced lung injury in the rat. The role of epithelial neutrophil activating protein . J Clin Invest 1995; 95: 134-141.

24.

Liang P. , Pardee AB Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction. Science 1992; 257: 967-971.

25.

Liang P. , Averboukh L. , Pardee AB Distribution and cloning eukaryotic mRNAs by means of differential display: refinements and optimization. Nucleic Acid Res 1994; 21: 3269-3275.

26.

Palleroni AV , Varesio L. , Wright RB et al. Tumoricidal alveolar macrophage and tumor infiltrating macrophage cell lines. Int Cancer 1991; 49: 296-302.